Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) announced great clinical data from its SCOPE melanoma trial for iSCIB1+. The drug showed a 74% progression-free survival rate at 16 months, beating the standard-of-care benchmark. Watch more
Poolbeg Pharma PLC (AIM:POLB, OTC:POLBF) is the lead business partner in the new £3.4 million RISE research program. This initiative will focus on cytokine release syndrome (CRS), making its POLB 001 trial a central component. Watch more
Optima Health PLC (AIM:OPT) posted strong first-half results, achieving 17% revenue growth driven by both organic expansion and new acquisitions. The company is also mobilising its massive £210 million contract for the UK Armed Forces. Watch more
SkinBioTherapeutics PLC (AIM:SBTX) is celebrating a fantastic year, with revenue surging by 284% to £4.6 million. The company is boosting growth through new retail deals and integrating recent strategic acquisitions. Watch more
Follow us and subscribe on YouTube, our social channels and on proactiveinvestors.co.uk.